The Polio Eradication and Endgame Strategic Plan

Part 1: Technical Rationale for IPV Introduction and OPV Withdrawal

GPEI Accomplishment Significant Decline in Paralysis Due

to WPVs, 1988 to 2013*

Poliovirus Types

IPV

Number of Cases of cVDPV-related Polio Exceeds the Number of Cases

of WPV

Polio Eradication and Endgame Strategic Plan 2013 to 2018

Polio Eradication and Endgame Strategic Plan

Objectives

Objective 2 Strengthen Immunization Systems, Introduce

IPV, and Withdraw OPV

SAGE Recommendations for the Planned Use of IPV

Introducing at Least 1 Dose of IPV Before the tOPV → bOPV Switch

Rationale: Improve Global Population Immunity

Individual Protection Against IPV-induced Paralytic Disease

Reducing the Risks

Individual Protection Against IPV-induced Paralytic Disease

Reducing the Risks

Individual Protection Against IPV-induced Paralytic Disease

Reducing the Risks

Poliovirus Shedding in IPV vs OPV After Virus Vaccine Challenge

IPV and Polio Eradication

Recommended IPV ScheduleKey Points

Programmatic Implications of IPV Introduction

Global Introduction of IPV

Introducing IPV in 124 CountriesA Coordinated, Multipartner Effort

IPV Vaccine DemandForecast and Supply

IPV Presentations and Formulations

IPV Prices for Supply Through UNICEF (2014 to 2018)

GAVI Support for IPVGAVI Alliance Board of Director Decisions, November

2013*

Administration of IPV

Advantages of Administering Multiple Injections at Same Visit

IPV Is Temperature Sensitive

IPV Impact of 1-dose Vial on Central-level Cold Chain in DR

Congo Is Limited

IPV Multidose Vials

Technical and Communication Resources for Planning and IPV

Introduction

Considerations for Planning and LogisticsSummary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)